AIMS: We performed this retrospective study to evaluate the value of clinicopathological factors and a novel molecular marker stathmin in predicting treatment response to neoadjuvant chemotherapy (NCT) with docetaxel-containing regimens in patients with locally advanced breast cancer. METHODS: Fifty-four consecutive locally advanced patients receiving docetaxel-containing NCT between January 2006 and July 2010 in Zhejiang Cancer Hospital were included. The expression levels of estrogen receptor (ER), progesterone receptor (PgR), epidermal growth factor receptor-2 (HER-2), and p53 were detected by immunohistochemistry, while expression of stathmin mRNA was measured by Quanti-Gene assay. RESULTS: The overall clinical objective response (cOR) rate was 75.9% (41/54) in breast. A total of 34 patients (63.0%) experienced pathological OR (pOR), with pathological complete remission (pCR) rate of 20.4% (11/54) in breast and 16.7% (9/54) in both breast and axilla. In univariate analysis, there were associations of pOR in both breast and axilla with age (p=0.054), ER status (p=0.059), subtypes (p=0.062), p53 (p=0.030), and stathmin expression (three terciles) (p=0.039). Mean expression of stathmin in pOR group was 0.410, compared with that in no response group of 0.556 (p=0.051 by Student's t-test). Similarly, a lower expression of stathmin might represent a higher pCR rate (p=0.061). Moreover, the LOWESS smoothing plot showed the same trend, that is, that tumor with a lower level of stathmin expression had a higher probability of response to docetaxel-containing NCT. After multivariate adjustment, both ER and stathmin remained significant with hazard ratio of 4.58 (95% CI: 1.11-18.94, p=0.036) and 2.94 (95% CI: 1.26-6.86, p=0.012), respectively. CONCLUSIONS: In conclusion, ER and stathmin were independent predictive factors for NCT with docetaxel-containing regimens.
AIMS: We performed this retrospective study to evaluate the value of clinicopathological factors and a novel molecular marker stathmin in predicting treatment response to neoadjuvant chemotherapy (NCT) with docetaxel-containing regimens in patients with locally advanced breast cancer. METHODS: Fifty-four consecutive locally advanced patients receiving docetaxel-containing NCT between January 2006 and July 2010 in Zhejiang Cancer Hospital were included. The expression levels of estrogen receptor (ER), progesterone receptor (PgR), epidermal growth factor receptor-2 (HER-2), and p53 were detected by immunohistochemistry, while expression of stathmin mRNA was measured by Quanti-Gene assay. RESULTS: The overall clinical objective response (cOR) rate was 75.9% (41/54) in breast. A total of 34 patients (63.0%) experienced pathological OR (pOR), with pathological complete remission (pCR) rate of 20.4% (11/54) in breast and 16.7% (9/54) in both breast and axilla. In univariate analysis, there were associations of pOR in both breast and axilla with age (p=0.054), ER status (p=0.059), subtypes (p=0.062), p53 (p=0.030), and stathmin expression (three terciles) (p=0.039). Mean expression of stathmin in pOR group was 0.410, compared with that in no response group of 0.556 (p=0.051 by Student's t-test). Similarly, a lower expression of stathmin might represent a higher pCR rate (p=0.061). Moreover, the LOWESS smoothing plot showed the same trend, that is, that tumor with a lower level of stathmin expression had a higher probability of response to docetaxel-containing NCT. After multivariate adjustment, both ER and stathmin remained significant with hazard ratio of 4.58 (95% CI: 1.11-18.94, p=0.036) and 2.94 (95% CI: 1.26-6.86, p=0.012), respectively. CONCLUSIONS: In conclusion, ER and stathmin were independent predictive factors for NCT with docetaxel-containing regimens.
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Philippe Bertheau; Elisabeth Turpin; David S Rickman; Marc Espié; Aurélien de Reyniès; Jean-Paul Feugeas; Louis-François Plassa; Hany Soliman; Mariana Varna; Anne de Roquancourt; Jacqueline Lehmann-Che; Yves Beuzard; Michel Marty; Jean-Louis Misset; Anne Janin; Hugues de Thé Journal: PLoS Med Date: 2007-03 Impact factor: 11.069
Authors: Henry D Reyes; Jeffrey Miecznikowski; Jesus Gonzalez-Bosquet; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Jean-Marie Stephan; Parviz Hanjani; Saketh Guntupalli; Krishnansu S Tewari; Floor Backes; Nilsa Ramirez; Gini F Fleming; Virginia Filiaci; Michael J Birrer; Kimberly K Leslie Journal: Gynecol Oncol Date: 2017-05-19 Impact factor: 5.482
Authors: T Powrózek; R Mlak; P Krawczyk; S Bartoń; B Biernacka; T Małecka-Massalska; J Milanowski Journal: Clin Transl Oncol Date: 2015-07-07 Impact factor: 3.405
Authors: T Powrózek; R Mlak; P Krawczyk; I Homa; M Ciesielka; P Kozioł; M Prendecka; J Milanowski; T Małecka-Massalska Journal: Clin Transl Oncol Date: 2015-07-21 Impact factor: 3.405
Authors: Michelle J Nyhan; Tracey R O'Donovan; Antonius W M Boersma; Erik A C Wiemer; Sharon L McKenna Journal: BMC Cancer Date: 2016-02-15 Impact factor: 4.430